The United Nations Convention on Biological Diversity, or COP16, ended on Nov. 2. Several days before delegations from 177 ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

The FDA has lifted clinical holds on trials of zevor-cel, satri-cel, and CT071, and trials will now resume in the US.

The upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of $1.91 per share, indicating a decline of 37.4% compared to the year-ago period. Analysts forecast revenues of $1.25 ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty ...

Current Moderna shareholders who have held Moderna shares since on or before January 18, 2023, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a ...

The Centers for Disease Control and Prevention now recommends that people ages 65 and up and those with weakened immune ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene ...

By Mark Gargarian Noubar and Anna Afeyan first met in 1986 at an American Chemical Society meeting in Anaheim, Calif. Noubar ...